Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.

Clinical Oncology (Royal College of Radiologists (Great Britain)

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, administration & dosage, adverse effects, analogs & derivatives, Colorectal Neoplasms, drug therapy, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Salvage Therapy, Survival Rate

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial.

      Related collections

      Author and article information

      Journal
      18155454
      10.1016/j.clon.2007.11.008

      Comments

      Comment on this article